Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lin-Li Li

Showing results (51-60 of 66) with videos related to

Pageof 7
Sort By:
Bioorganic & Medicinal Chemistry Letters|February 1, 2020
Discovery of thieno[2,3-d]pyrimidin-4(3H)-one derivatives as a new class of ROCK inhibitorsZhuang Miao, Yu-Meng Sun, Lan-Ying Zhao, et al.
Bioorganic & Medicinal Chemistry Letters|May 26, 2017
Discovery of pyrazolo[1,5-a]pyrimidine-3-carbonitrile derivatives as a new class of histone lysine demethylase 4D (KDM4D) inhibitorsZhen Fang, Tian-Qi Wang, Hui Li, et al.
Journal of Chemical Information and Modeling|May 31, 2011
Discovery of novel Pim-1 kinase inhibitors by a hierarchical multistage virtual screening approach based on SVM model, pharmacophore, and molecular dockingJi-Xia Ren, Lin-Li Li, Ren-Lin Zheng, et al.
Bioorganic & Medicinal Chemistry Letters|July 15, 2011
Discovery of novel fatty acid synthase (FAS) inhibitors based on the structure of ketoaceyl synthase (KS) domainXiao-Fei Zeng, Wei-Wei Li, Hui-Jin Fan, et al.
Journal of Medicinal Chemistry|February 1, 2013
Structure-activity relationship studies of pyrazolo[3,4-d]pyrimidine derivatives leading to the discovery of a novel multikinase inhibitor that potently inhibits FLT3 and VEGFR2 and evaluation of its activity against acute myeloid leukemia in vitro and in vivoLing-Ling Yang, Guo-Bo Li, Shuang Ma, et al.
Plos One|December 24, 2011
Systems biology modeling reveals a possible mechanism of the tumor cell death upon oncogene inactivation in EGFR addicted cancersJian-Ping Zhou, Xin Chen, Shan Feng, et al.
Bioorganic & Medicinal Chemistry Letters|October 3, 2015
Discovery and structure-activity analysis of 4-((5-nitropyrimidin-4-yl)amino)benzimidamide derivatives as novel protein arginine methyltransferase 1 (PRMT1) inhibitorsXu-Ri Yu, Yun Tang, Wen-Jing Wang, et al.
Scientific Reports|October 27, 2015
SKLB-677, an FLT3 and Wnt/β-catenin signaling inhibitor, displays potent activity in models of FLT3-driven AMLShuang Ma, Ling-Ling Yang, Ting Niu, et al.
Journal of Medicinal Chemistry|July 11, 2017
Discovery of Potent and Selective Inhibitors of Cdc2-Like Kinase 1 (CLK1) as a New Class of Autophagy InducersQi-Zheng Sun, Gui-Feng Lin, Lin-Li Li, et al.
Molecular Cancer Therapeutics|January 2, 2016
Preclinical Evaluation of a Novel Orally Available SRC/Raf/VEGFR2 Inhibitor, SKLB646, in the Treatment of Triple-Negative Breast CancerMing-Wu Zheng, Chun-Hui Zhang, Kai Chen, et al.
Pageof 7

Showing results (51-60 of 66) with videos related to

Sort By:
Pageof 7
Bioorganic & Medicinal Chemistry Letters|February 1, 2020
Discovery of thieno[2,3-d]pyrimidin-4(3H)-one derivatives as a new class of ROCK inhibitorsZhuang Miao, Yu-Meng Sun, Lan-Ying Zhao, et al.
Bioorganic & Medicinal Chemistry Letters|May 26, 2017
Discovery of pyrazolo[1,5-a]pyrimidine-3-carbonitrile derivatives as a new class of histone lysine demethylase 4D (KDM4D) inhibitorsZhen Fang, Tian-Qi Wang, Hui Li, et al.
Journal of Chemical Information and Modeling|May 31, 2011
Discovery of novel Pim-1 kinase inhibitors by a hierarchical multistage virtual screening approach based on SVM model, pharmacophore, and molecular dockingJi-Xia Ren, Lin-Li Li, Ren-Lin Zheng, et al.
Bioorganic & Medicinal Chemistry Letters|July 15, 2011
Discovery of novel fatty acid synthase (FAS) inhibitors based on the structure of ketoaceyl synthase (KS) domainXiao-Fei Zeng, Wei-Wei Li, Hui-Jin Fan, et al.
Journal of Medicinal Chemistry|February 1, 2013
Structure-activity relationship studies of pyrazolo[3,4-d]pyrimidine derivatives leading to the discovery of a novel multikinase inhibitor that potently inhibits FLT3 and VEGFR2 and evaluation of its activity against acute myeloid leukemia in vitro and in vivoLing-Ling Yang, Guo-Bo Li, Shuang Ma, et al.
Plos One|December 24, 2011
Systems biology modeling reveals a possible mechanism of the tumor cell death upon oncogene inactivation in EGFR addicted cancersJian-Ping Zhou, Xin Chen, Shan Feng, et al.
Bioorganic & Medicinal Chemistry Letters|October 3, 2015
Discovery and structure-activity analysis of 4-((5-nitropyrimidin-4-yl)amino)benzimidamide derivatives as novel protein arginine methyltransferase 1 (PRMT1) inhibitorsXu-Ri Yu, Yun Tang, Wen-Jing Wang, et al.
Scientific Reports|October 27, 2015
SKLB-677, an FLT3 and Wnt/β-catenin signaling inhibitor, displays potent activity in models of FLT3-driven AMLShuang Ma, Ling-Ling Yang, Ting Niu, et al.
Journal of Medicinal Chemistry|July 11, 2017
Discovery of Potent and Selective Inhibitors of Cdc2-Like Kinase 1 (CLK1) as a New Class of Autophagy InducersQi-Zheng Sun, Gui-Feng Lin, Lin-Li Li, et al.
Molecular Cancer Therapeutics|January 2, 2016
Preclinical Evaluation of a Novel Orally Available SRC/Raf/VEGFR2 Inhibitor, SKLB646, in the Treatment of Triple-Negative Breast CancerMing-Wu Zheng, Chun-Hui Zhang, Kai Chen, et al.
Pageof 7